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Abstract
Mendelian randomization (MR) is a powerful approach to examine the causal
relationships between health risk factors and outcomes from observational studies.
Due to the proliferation of genome-wide association studies (GWASs) and abundant
fully accessible GWASs summary statistics, a variety of two-sample MR methods
for summary data have been developed to either detect or account for horizontal
pleiotropy, primarily based on the assumption that the effects of variants on exposure
(γ) and horizontal pleiotropy (α) are independent. This assumption is too strict
and can be easily violated because of the correlated horizontal pleiotropy (CHP). To
account for this CHP, we propose a Bayesian approach, MR-Corr2, that uses the
orthogonal projection to reparameterize the bivariate normal distribution for γ and
α, and a spike-slab prior to mitigate the impact of CHP. We develop an efficient
algorithm with paralleled Gibbs sampling. To demonstrate the advantages of MR-Corr2
over existing methods, we conducted comprehensive simulation studies to compare
for both type-I error control and point estimates in various scenarios. By applying
MR-Corr2 to study the relationships between pairs in two sets of complex traits,
we did not identify the contradictory causal relationship between HDL-c and CAD.
Moreover, the results provide a new perspective of the causal network among complex
traits. The developed R package and code to reproduce all the results are available at
https://github.com/QingCheng0218/MR.Corr2.
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1 Introduction
Inferring causal relationships from observational studies is particularly challenging because
of unmeasured confounding, reverse causation and selection bias [12]. Without adjusting for
confounding effects, the relationships obtained from epidemiological studies might be pure
associations due to common confounders between the health risk factors (exposures) and
outcomes. Conventionally, associations established from randomized controlled trial (RCT)
can be taken to be causal as the relationship between potential confounders and health risk
factors is broken by randomization. Alternatively, Mendelian randomization (MR) is a study
design that can be used to examine the causal effects between exposures and outcomes from
observation studies, by mitigating the impact from the unobserved confounding factors [12].
As germline genetic variants (single nucleotide polymorphisms, SNPs) are fixed after random
mating and independent of subsequent factors, e.g., environment factors and living styles,
MR can be taken as a special case of instrumental variable (IV) methods [14], which has a
long history in econometrics and statistics.
As a category of methods closely related to IV methods, MR methods require certain
assumptions to hold, as shown in Figure 2, to infer the causal relationships between the
exposures and outcomes. To relax the exclusion assumption (IV3 in Figure 2), a variety of
methods have been developed either to detect horizontal pleiotropy, e.g., Q test [17], modified
Q test [4], GSMR [43], and MR-PRESSO [37], or to account for horizontal pleiotropy in a joint
model, e.g., MR-Egger [2], MMR [6], sisVIVE [23], RAPS [41], MRMix [32], BWMR [40] and
MR GENIUS [36]. Most developed methods here rely on the instrument strength independent
of direct effect (InSIDE) condition [3], which requires the independence between the effects
of genetic variants on exposure and horizontal pleiotropy. This crucial assumption for zero
correlation was first identified in econometrics literature for IV analysis with direct effects [24]
and later applied in various MR analysis [41, 9]. However, in practice, this assumption is
too strict and can be easily violated. Our motivating example below shows that there exists
heteroscedasticity in the linear relationships between many exposure and outcome pairs,
indicating the substantial amount of correlation between the effects of genetic variants on
exposure and horizontal pleiotropy. Without correcting for this correlation, MR methods can
lead to biased estimates and inflated false-positive causal relationships [27]. Recently, [27]
proposed a new MR method, Causal Analysis Using Summary Effect estimates (CAUSE), to
infer causal effects by removing correlated pleiotropy, that is genetic variants affecting both
the exposure and outcome through the unobserved confounders. Our numerical studies show
that CAUSE suffers from severe p-value deflation. Statistically rigorous methods are needed
to address the problem of heteroscedasticity due to correlated horizontal pleiotropy (CHP)
in MR.
On the other hand, most of the classical MR methods are regression-based, e.g., inverse
variance weighting (IVW) [5] and MR-Egger [2], and only work for independent genetic
variants. As linkage disequilibrium (LD) is a key feature in GWASs, a few methods have been
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developed to account for correlations among instruments, e.g., GSMR [43], and MR-LDP [9].
Among them, GSMR can only account for weak or moderate correlations among instruments
while MR-LDP can deal with weak instruments from strong correlations. However, none of
these methods adjust for CHP.
This paper aims to resolve the issue of correcting for CHP using correlated genetic variants
by developing Bayesian models using GWAS summary statistics. In the following, we will
briefly introduce the background of MR study, show the problems of MR using a motivating
example, discuss the challenges to correct CHP in MR and the need to incorporate weak
instruments, and conclude the introduction by outlining our solution.
1.1 Two-sample MR using GWAS summary statistics
As shown in Figure 2, we are interested in inferring causality between an exposure X and
an outcome Y , where X and Y are confounded by unobserved confounding factors. For
the ease of presentation, we assume that genetic variants, G1, G2, . . . , Gp, are independent
here and refer Section 2.4 for details using correlated genetic variants. The corresponding
GWAS summary statistics for SNP-exposure and SNP-outcome are denoted as {γ̂k, ŝ2γk}
and {Γ̂k, ŝ2Γk}, ∀k = 1, . . . , p, usually by performing a simple linear or logistic regression of
either exposure X or outcome Y on each of the genetic variants. Assuming that independent
samples are used for SNP-exposure and SNP-outcome, for each variant k, we have
γ̂k ∼ N (γk, ŝ2γk), Γ̂k ∼ N (Γk, ŝ2Γk), (1)
where γk and Γk are underlying true coefficients for SNP-exposure and SNP-outcome on
variant k, respectively. Following the linear structural model (5) in Section 2.1, we can
construct a linear relationship between γk and Γk,
Γk = β0γk + αk, k = 1, . . . , p, (2)
where αk ∼ N (0, σ2α), capturing the direct effects of genetic variants on a health outcome.
Combining Eqn. (1) and (2), various MR methods have been developed to estimate the
causal effect β0, e.g., RAPS [41], but they are all based on the InSIDE condition, namely,
γk and αk are independent. If there is correlation between γk and αk, causal effect β0 is
not identifiable in Eqn. (2). Intuitively, this non-identifiability can be easily observed from
a perspective of linear regression with correlation between the explanatory variable and
residuals.
1.2 A motivating example
Next we introduce a real data example that is used in the real data analysis. In this example,
we are interested in estimating the causal effect of high-density lipoprotein cholesterol (HDL-
c) on coronary artery disease (CAD). We obtained summary statistics from three GWASs
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Figure 1: Scatter plot of Γ̂k against γ̂k between CAD and HDL-c. The vertical and horizontal
segments represent the standard errors of Γ̂k and γ̂k, respectively, at each point. To ease the
presentation, we orient the reference alleles so that γ̂k is positive. For each data point, we
use a spectrum of color bar to represent the mean value of latent indicators ηk. The blue line
represents the causal effect βˆ0 of HDL-c on CAD while the red line represents the nuisance
parameter βˆ1, see Eqn. 7.
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without overlapping samples, see Table S2 in the Supplementary document.
Using HDL-c from Biobank Janpan [22] as a screening dataset, we selected 62 SNPs that
have p-value less than 1× 10−6 and uncorrelated (through SNP clumping; [31]). We then
obtain the summary statistics {γ̂k, ŝ2γk} and {Γ̂k, ŝ2Γk}, k = 1, . . . p, for the SNP-HDL-c and
and SNP-CAD, respectively. The scatter plot of Γ̂k against γ̂k for the 62 pairs of genetic effects
with their standard errors is shown in Figure 1. By assuming the systematic independent
horizontal pleiotropy (IHP), a linear relationship 2 can be applied to estimate causal effect
β0. However, due to CHP, there exists heteroscedasticity in this linear relationship. With
larger γ̂k, the variance of Γ̂k becomes larger. The statistical method should overcome this
heteroscedasticity to produce robust causal estimates.
1.3 Methodological challenges and organization of the paper
Similar to its related IV methods, how to correct for CHP or correlated direct effects remains
the biggest challenge for MR methods using GWAS summary statistics. As discussed in
Section 1.1, there exists non-identifiability issues when we use a bivariate normal distribution
for γk and αk. To tackle this issue, we propose a strategy using a mixture of linear
regressions via orthogonal projection assuming the horizontal pleiotropy is sparse. In general,
this strategy can be applied to other IV methods to mitigate the impact of correlated direct
effects.
Compared to IV methods and MR methods that use the individual-level data, most of
classical MR methods for summary data cannot handle the correlations among instrumental
variants. Usually, two variants close in distance tend to have high correlations. Moreover,
these correlations decay exponentially in genetic distance. Because of correlations among
genetic variants, it is not valid to use i.i.d. normal distribution (1) for GWAS summary
statistics from a dense set of SNPs. Recently, we developed MR-LDP [9] to infer causal
effects using correlated weak instrumental variants accounting for both linkage disequilibrium
and IHP. MR methods using correlated genetic variants will improve the statistical efficiency
for point estimation. To model summary statistics from correlated SNPs, the key is to
use multivariate normal distributions to approximate the joint distributions of γ̂ and Γ̂.
The details of this approximated likelihood for GWAS summary statistics are given in the
Supplementary document.
In this paper, we propose a unified and statistically efficient two-sample MR method
to account for CHP using weak instrumental variants. To ease the presentation, we will
consider the following two nested models using GWAS summary statistics:
MODEL 1 (MR-Corr). Accounting for CHP using independent instrumental variants.
MODEL 2 (MR-Corr2). Accounting for CHP using correlated instrumental variants.
The rest of the paper is organized as follows. In Section 2, we first review the linear
structural models to estimate causal effects followed by introducing the mixture of linear
regressions via orthogonal projection. We also introduce MR-Corr and MR-Corr2 methods
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Figure 2: Direct acyclic graph of MR and three IV assumptions. IV1: genetic variants (Gks)
are associated with the exposure (relevance); IV2: Gks are not associated with unobserved
confounders (independence); IV3: Gks have no direct effects on the outcome (exclusion). To
relax the exclusion assumption (IV3), most methods assume the InSide condition that γk
and αk are independent.
in this Section. In Section 3, we connect MR-Corr with existing methods. In Section 4, we
perform simulation studies to benchmark the performance of MR-Corr2. In Section 5, we
first apply the proposed method for the analysis of a real validation using the height-height
example, and then apply MR-Corr2 to analyze GWAS summary statistics from two sets of
traits.
2 Methods
2.1 Linear structural models and MR
In this Section, we illustrate how MR methods work in the absence/presence of IHP using
linear structural models [3, 41].
In MR analysis, we are interested in inferring causal relationship between an exposure
X and an outcome Y , with unobserved confounding factors U . The classical MR analysis
obeys the following three assumptions in the IV methods, as shown in Figure 2:
1. The relevance assumption: The instrument G is associated with the exposure X.
2. The independence assumption: G is independent of confounders U .
3. The exclusion assumption: G affects the outcome Y only through the exposure X.
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Assuming the validity of instrumental variants, we begin with the linear structural model,
X =
p∑
k=1
γkGk + ηxU + x, Y = β0X + ηyU + y, (3)
where β0 is the causal effect of interest, ηx and ηy are effects of confounding factors on
exposure and outcome, respectively, x and y are independent random noises, (x, y) ⊥
⊥ (G1, . . . , Gp, U), x ⊥⊥ y, and U ⊥⊥ (G1, . . . , Gp). In two-sample MR, we observe two
independent samples with sample sizes nx and ny for (X,G1, . . . , Gp) and (Y,G1, . . . , Gp),
respectively. Clearly, Eqn. (3) satisfying the exclusion assumption as (G1, . . . , Gp) ⊥⊥ Y |X.
By replacing X in the second equation with the first equation in Eqn. (3), we have
Y =
p∑
k=1
β0γkGk + (β0ηx + ηy)U + β0x + y.
Therefore, the effect Γk of variant k on the health outcome can be written as
Γk = β0γk,∀k = 1, . . . , p. (4)
In practice, the exclusion assumption can be easily violated because of ubiquitous
horizontal pleiotropy or direct effects. Similar to Eqn. (3), the linear structural model
incorporating horizontal pleiotropy αk, on each variant k can be written as
X =
p∑
k=1
γkGk + ηxU + x, Y =
p∑
k=1
αkGk + β0X + ηyU + y, (5)
Again, by replacing X in the second equation with the first equation in Eqn. (5), we have
Y =
p∑
k=1
(β0γk + αk)Gk + (β0ηx + ηy)U + β0x + y.
Thus, the effect Γk of variant k on the health outcome can be written as Eqn. (2).
In practice, performing causal inference using either Eqn. (3) or Eqn. (5) is impractical
as it requires individual-level data, Fortunately, GWAS summary statistics are publicly
accessible. Suppose that we obtain summary statistics for health risk factor and (disease)
outcome as {γ̂k, ŝ2γk} and {Γ̂k, ŝ2Γk},∀k = 1, . . . , p, respectively, from two independent samples,
where p is the number of genetic variants. To ease the presentation, we first consider summary
statistics for a set of independent genetic variants by SNP clumping. The corresponding
MR-Corr model is introduced in Section 2.3. Later, we extend our model to incorporate
genetic variants within LD and introduce MR-Corr2 in Section 2.4. For independent genetic
variants, their distributions for summary statistics can be written as Eqn. (1). To further
account for horizontal pleiotropy, various MR methods have been developed to estimate
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the causal effect β0 by assuming that α ⊥⊥ γ (the InSIDE condition). In genetic studies,
the InSIDE condition may not hold due to heteroscedasticity in γ and α. In Section 3, we
provide a perspective to treat CHP by connecting our methods with CAUSE.
Remark 1: From the linear structural model (3), we know that when the classical IV
assumptions (Figure 2) hold, there exists a deterministic linear relationship between Γk and
γk, ∀k = 1, . . . , p, i.e., Eqn. (4). The resulting absolute correlation, denoted as |ρg|, between
Γ and γ will be the exact 1, which is unrealistic as the absolute value of genetic correlation
between any two distinct traits can never be 1. Note that ρg is different from ραγ , which is
the correlation between γ and α. On the other hand, the linear relationship with systematic
IHP in Eqn. (2) is more flexible, resulting a correlation that |ρg| < 1.
2.2 Mixture of linear regressions via orthogonal projection
To correct for CHP, we develop a strategy using a mixture of linear regressions (MLR) via
orthogonal projection. Our key idea is based on the following observation. For the ease of
presentation, we assume that instrumental variants are independent here and will generalize
this strategy to handle correlated instrumental variants in Section 2.4. Suppose that the
effects of genetic variant on exposure and horizontal pleiotropy follow a bivariate normal
distribution for each variant k,(
γk
αk
)
∼ N
(
0,
(
σ2γ , ραγ σγσα0
ραγ σγσα0 , σ
2
α0
))
, (6)
where ραγ is the correlation between γk and αk. Clearly, from Eqn. (6), we have
γk ∼ N (0, σ2γ),
αk = ραγ
σα0
σγ
γk +
√
1− ρ2αγσα0Zk def= cγk + α˜k,
where Zk ⊥⊥ γk and Zk ∼ N (0, 1). In this way, αk can be decomposed into two parts, one
is in a linear relationship with γk and the other is independent of γk, i.e., α˜k ⊥⊥ γk and
α˜k ∼ N (0, σ2α). We can further parameterize the causal relationship for genetic variant k as
follows
Γk =
{
β0γk, α˜k = 0
β1γk + α˜k, α˜k 6= 0,
(7)
where β0 is the causal effect of interest and β1 = β0 + ραγ σα0σγ is a nuisance parameter.
Therefore, to remove the impact of CHP in Eqn. (6) is equivalent to identifying zero
orthogonal projection of αk, namely α˜k = 0, in Eqn. (7). For this purpose, we may apply a
spike-slab prior on α˜k [19]. This observation motivates us to model Γk as a mixture of two
linear relationships with γk depending on the value of α˜k. Thus, using MLR strategy, the
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causal effect β0 can be estimated consistently by removing the impact of CHP as long as
correlation ραγ is not too close to 1 or -1.
2.3 MR-Corr model
In practice, the InSIDE condition may not hold due to the pervasive heteroscedasticity among
complex traits, resulting in correlations between horizontal pleiotropy, α, and effects on
exposure, γ. As shown in our simulations (Figure 4), a small deviation from zero correlation
may lead to severe inflation in type-I error, making MR methods not correcting for CHP
less reliable.
Here, we consider a Bayesian MR method via the MLR strategy to correct for CHP using
independent instrumental variants. Assuming the independence among instrumental variants
as well as independent samples for SNP-exposure and SNP-outcome, for each variant k,
γ̂k and Γ̂k are i.i.d. distributed as Eqn. (1). By introducing a latent indicator ηk for each
variant k, we assign a spike-slab prior on α˜k [19, 35],
α˜k ∼
{
N (0, σ2α), ηk = 1
δ0(αk), ηk = 0,
where N (0, σ2α) denotes a normal distribution with mean 0 and variance σ2α, δ0 denotes the
Dirac delta function at zero, ηk = 1 means the k-th genetic variant present nonzero orthogonal
projected pleiotropic effect, and ηk = 0 means zero orthogonal projected pleiotropic effect.
Here, ηk is a Bernoulli random variable with probability ω being 1, i.e., ηk ∼ ωηk(1−ω)1−ηk .
Using the reparameterization trick in Eqn. (7), the relationship between γ and Γ can be
constructed linearly as
Γk = β0(1− ηk)γk + β1ηkγk + ηkα˜k, (8)
where k = 1, . . . , p and γ ⊥⊥ α˜. Then, we propose the following hierarchical Bayesian model
for MR-Corr with MLR strategy to account for CHP,
Γ̂k|Γk i.i.d.∼ N (Γk, ŝ2Γk), γ̂k|γk
i.i.d.∼ N (γk, ŝ2Γk),
Γk = β0(1− ηk)γk + β1ηkγk + ηkα˜k,
γk|σ2γ i.i.d.∼ N (0, σ2γ), α˜k|σ2α i.i.d.∼ N (0, σ2α), ηk|ω i.i.d.∼ ωηk(1− ω)1−ηk ,
σ2γ ∼ IG(aγ , bγ), σ2α ∼ IG(aα, bα), ω ∼ Beta(a, b), (9)
where Jeffreys non-informative priors are used for both β0 and β1 and a spike-slab prior (8)
is reprameterized as α˜kωk. The detailed Gibbs sampling algorithm with pseudo codes can
be found in the Supplementary document.
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2.4 MR-Corr2 model
As MR-Corr (9) assumes the SNPs are independent, it does not work for instrumental
variants in LD. To further incorporate SNPs in LD for MR analysis, we develop MR-Corr2
here. The key is to build a joint summary statistics distribution for correlated SNPs. For
this purpose, we use the approximated distribution for summary statistics [42, 18],
γ̂|γ, R̂, Ŝγ ∼ N (ŜγR̂Ŝ−1γ γ, ŜγR̂Ŝγ),
Γ̂|Γ, R̂, ŜΓ ∼ N (ŜΓR̂Ŝ−1Γ Γ, ŜΓR̂ŜΓ), (10)
where Ŝγ = diag([̂sγ1 , · · · , ŝγp ]) and ŜΓ = diag([̂sΓ1 , · · · , ŝΓp ]) are both diagonal matrices,
γ̂ = [γ̂1, . . . , γ̂p]
T , Γ̂ = [Γ̂1, . . . , Γ̂p]T , γ = [γ1, . . . , γp]T , Γ = [Γ1, . . . ,Γp]T . Given that sample
size n is large enough and the trait is highly polygenic, i.e., the squared correlation coefficient
between the trait and each genetic variant is close to zero, Zhu and Stephens [42] showed that
difference between the likelihoods based on the individual-level data and summary statistics
is some constant that does not depend on γ under some regularity conditions (See Table
1 in [42] and Table S4 in [39] for numerical justifications). Details for this approximated
distribution can be found in Section S1.1.
As GWAS summary statistics does not contain any information for the correlation R̂,
we use an additional independent sample as reference data to estimate this correlation R̂ref .
In [18], we theoretically analyzed the impact of using reference sample to estimate this
correlation for l1 penalization and empirical results in [42, 18, 9] show that the distribution
for summary statistics approximates the individual-level one well. The details for the choice
of LD can be found in Section Section S1.2.
Next, we show how to use MLR strategy for correlated SNPs. Clearly, when there is a
single variant k with nonzero direct effect αk, the direct effect for a nearby variant k′ would
be nonzero as well. This is because variants k and k′ from the same LD are highly correlated.
Moreover, LD across the genome can be partitioned into independent blocks. SNPs within
the same block are correlated but SNPs from different blocks are independent. Thus, the
orthogonal projection α˜k should be in a group manner. Here, we introduce a group-level
latent status ηl, indicating whether genetic variants within the l-th block present nonzero
horizontal pleiotropy and assign a spike-slab prior on α˜lk [19, 35],
α˜lk ∼
{
N (0, σ2α), ηl = 1
δ0(αlk), ηl = 0,
(11)
where N (0, σ2α) denotes a normal distribution with mean 0 and variance σ2α, δ0 denotes
the Dirac delta function at zero, ηl = 1 means variants within the l-th block present nonzero
orthogonal projected pleiotropic effects or ηl = 0 means orthogonal projected pleiotropic
effects from variants within block l are all zero. Here, ηl is a Bernoulli random variable with
probability ω being 1, ηl ∼ ωηl(1− ω)1−ηl .
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Using the reparameterization trick in Eqn. (11), the relationship between γ and Γ can
be constructed linearly as:
Γlk = β0(1− ηl)ηlγlk + β1ηlγlk + ηlα˜lk, (12)
where l = 1, . . . , L, k = 1, . . . , pl and γlk ⊥⊥ α˜lk. Then we propose the following hierarchical
Bayesian model for MR-Corr2,
γ̂|γ, R̂, Ŝγ ∼ N (ŜγR̂Ŝ−1γ γ, ŜγR̂Ŝγ),
Γ̂|Γ, R̂, ŜΓ ∼ N (ŜΓR̂Ŝ−1Γ Γ, ŜΓR̂ŜΓ),
Γlk = β0(1− ηl)ηlγlk + β1ηlγlk + ηlα˜lk,
γlk|σ2γ i.i.d.∼ N (0, σ2γ), α˜lk|σ2α i.i.d.∼ N (0, σ2α), ηl|ω i.i.d.∼ ωηl(1− ω)1−ηl ,
σ2γ ∼ IG(aγ , bγ), σ2α ∼ IG(aα, bα), ω ∼ Beta(a, b). (13)
The corresponding parallel Gibbs sampling algorithm with pseudo codes can be found in the
Supplementary document.
3 Connections with Existing Methods
(a) Mechanism 1 (b) Mechanism 2
Figure 3: The causal mechanisms between exposure X and outcome Y . Mechanism 1 is the
classical one while mechanism 2 refers to correlated pleiotropy.
Recently, [27] proposed a CAUSE method to address the problem that genetic variants
affect both the exposure and outcome through a heritable shared factor and thus there
are two mechanisms that SNPs affect an outcome as shown in Figure 3. Here, to ease
the illustration, we consider only correlated pleiotropy for independent SNPs as shown in
Figure 3b. By assuming the effect of confounding factor U on exposure X is scaled to 1 and
considering the effect of U on Y is κ, the relationship between γk and Γk without considering
horizontal pleiotropy can be written as
Γk = β0γk + ηkκγk, (14)
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where ηk is an indicator of whether Gk affects U that has different meaning in MR-Corr.
Using the fact that β1 = β0 + κ, simple algebra shows that when α˜k → 0, Eqn. (8) reduces
to Eqn. (14). Thus, the CAUSE model with only correlated pleiotropy can be taken as an
extreme case of MR-Corr. By using the mechanism of CHP, the term κγk in Eqn. (14) can
be taken as horizontal pleiotropy but is fully correlated with γk with |ραγ | = 1. This only
happens when there is a single confounding factor U that affects both the exposure and
outcome. In this case, α˜k = 0 exactly as long as this single confounder has a scaled effect κ on
Y . However, when there are multiple confounding factors (U1, . . . , Uq) and these confounding
factors affect the outcome through some mediators as well as present direct effects, the
relationship between these confound factors and outcome Y would therefore show deviations
from the deterministic linear relationship with random errors. These random errors could
represent the independent direct effects between multiple confounders and outcome. In this
case, α˜k would not be 0 and Eqn. (8) holds.
Moreover, the identifiability of CAUSE model is up to the identifiability of indicator
ηk. Moreover, the consistency of estimating causal effects β0 depends on how well one can
estimate ηk. Compared to identify which mechanism is applied to a genetic variant as in
CAUSE, identifying whether α˜k is 0 is much easier and also identifiable. As our methods
avoid the case that |ραγ | lies on the boundary, there will be no identifiablity problems.
Because of the existence of CHP, in many cases, one would observe that many SNPs do not
obey either Eqn. (4) or Eqn. (2). RAPS and BWMR tackle this issue by treating these SNPs
as idiosyncratic outliers. Despite the fact that estimating causal effect using either Eqn. (4)
or Eqn. (2) is similar to performing a linear regression, treating SNPs that do not obey these
relationships as idiosyncratic outliers is not justified. This is because we work on the true
effect sizes γ and Γ without measurement errors. There should exist mechanisms that cause
this phenomenon and CHP is one of them. As one can observed in Figure 1, when the value
of γ̂k is large, the variation of Γ̂k is large, causing the variance of “residuals" to increase
with the ’predictor variable’ γ̂k. In the literature on linear regression, variance-stabilizing
transformation can be applied, e.g. Box-Cox transformation [34]. However, this technique
is not applicable in MR as we work on unobserved estimated effects γ̂ and Γ̂ instead of
the true effects of them. Fortunately, only SNPs with CHP would present this problem as
idiosyncratic outliers and MLR strategy can effectively mitigate the impact from these SNPs.
4 Simulation Studies
4.1 Simulation settings
In this section, we performed simulation studies to evaluate the performance of MR-Corr2.
In this simulation, we considered two scenarios: 1) The generative model for individual-level
data generated as Eqn. 15 with correlated α and γ; 2) The correlated pleiotropy model in
CAUSE setting as shown in Figure 3.
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In Scenario 1, we used the following structural model to generate individual-level data
x = G1γ + Uxηx + e1, y = β0x + G2α + Uyηy + e2, (15)
where G1 ∈ Rn1×p and G2 ∈ Rn2×p are genotype matrices for two samples, Ux ∈ Rn1×r
and Uy ∈ Rn2×r are matrices for confounding variables, n1 and n2 are the corresponding
sample sizes that are set at 20,000, p is the number of genetic variants, x ∈ Rn1×1 is the
exposure vector, y ∈ Rn2×1 is the outcome vector, and e1 and e2 are independent random
errors. Note that Eqn. (15) is the sample version of the linear structural model (5).
In Scenario 2, we first generated q from Beta(1, 10) as in [27]. Then we divided all p
genetic variants into two groups corresponding to two mechanisms in Figure 3(a) and (b),
respectively, with proportion 1 − q and q. For genetic variants with proportion 1 − q in
mechanism 1 (Figure 3(a)), the exposure vector was generated as
x1 = G11γ
1 + U1xη
1
x + e
1
1,
where subscript indicates which mechanism is active, G11 is the genotype matrix in SNP-
exposure sample for the genetic variants from mechanism 1 and γ1 is the corresponding
coefficient vector. For the remaining SNPs, the exposure vector was generated as
U2x = G
2
1γ
2 + eU, x
2 = U2x + e
2
1,
where G21 is the genotype matrix in SNP-exposure sample for the genetic variants from
mechanism 2 and γ2 is the corresponding coefficient vector. By combining these two
mechanisms, the outcome vector can be generated as
x = x1 + x2, y = β0x + G2α + Uyηy + e2.
For both scenarios, we first generated genotype matrices from multivariate normal
distribution N (0,Σ(ρ)), where Σ(ρ) is a block autoregressive (AR) with ρ = 0.4, or
0.8 representing moderate or strong LD, respectively. The genotype matrices were then
categorized into dosage values {0, 1, 2} according to the Hardy-Weinberg equilibrium using
the minor allele frequencies drawn from a uniform distribution U(0.05, 0.5). Moreover, we
assumed that γk and αk from a bivariate normal distribution N (0,Σ(ραγ)), where ραγ is
the correlation between αk and γk. We varied ραγ ∈ {0, 0.2.0.4}. In addition, we considered
α to be sparse, i.e., only a fraction of αk was from this bivariate normal distribution and
others are zero. The sparsity was fixed at 10%.
For confounding variables, we sampled each column of Ux and Uy from a standard
normal distribution with fixed r = 50. For their corresponding coefficients ηx ∈ Rr×1 and
ηy ∈ Rr×1, each row of (ηx,ηy) was generated from a multivariate normal distribution
N (0,Ση), where Ση is a two-by-two matrix with diagonal elements set as 1 and off-diagonal
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elements set as 0.8.
We then conducted single-variant analysis to obtain the summary statistics for SNP-
exposure and SNP-outcome, {γ̂k, ŝ2γk}k=1,··· ,p and {Γ̂k, ŝ2Γk}k=1,··· ,p, respectively. In sim-
ulations, we controlled the signal magnitude for both γ and α using their corresponding
heritability, h2γ =
var(β0G1γ)
var(y) and h
2
α =
var(G2α)
var(y) , respectively. Thus, we could control h
2
α
and h2γ at any value by controlling confounding variables, and the error terms, σ2e1 and σ
2
e2 .
In all settings, we fixed h2γ = 0.1 and varied h2α ∈ {0.05, 0.1}.
4.2 Simulation results
We benchmark the performance of MR-Corr2 using correlated SNPs, i.e., ρ = 0.4 and 0.8,
in comparison with alternative methods, including MR-LDP, CAUSE, GSMR, MRMix and
RAPS. In this simulation, we set the number of blocks L to be 100 or 200 and the number of
SNPs within a block to be 10. Thus we have p= 1,000 or 2,000 in total. As MR-Corr2 and
MR-LDP need an additional reference data to estimate LD, we generated an independent
reference panel G3 with sample size 500. Next we applied all six methods on the simulated
summary statistics as shown in Section 4.1. Since MR-Corr, CAUSE, GSMR, MRMix and
RAPS cannot account for strong correlated SNPs, we conducted SNP clumping to obtain
independent SNPs for making fair comparisons on point estimates.
In different scenarios, we evaluated type-I error under the null that β0 = 0 while we set
β0 = 0.1 to evaluate point estimates under the alternative. We ran 1,000 and 100 replicates
to assess type-I error and point estimates, respectively. Figure 4 shows type-I error and
point estimates of all methods when ραγ = 0.2. As we can see, MR-Corr2 can effectively
control type-I error in the presence of LD with CHP in both scenarios. While the type-I
error of MR-LDP is a little inflated in the second scenario, it is severely inflated in the case
of Scenario 1. Using all correlated SNPs, type-I errors for GSMR, MRMix and RAPS are
severely inflated. After performing SNP clumping, the inflation issue for GSMR is largely
reduced but there is deflated issue for MRMix. For point estimates, MR-Corr2 is unbiased
for all ραγ in both scenario and has the smallest standard errors while CAUSE is largely
biased. Comparing to other alternative methods, GSMR has smaller biasedness and standard
deviation for point estimates. The overall pattern is similar when ραγ = 0.4 as shown in
Figure S2. When ραγ becomes larger, the inflation of type-I error for MR-LDP in Scenario 1
is more severe. This is because MR-LDP accounts for only IHP but not CHP. We also shows
the results from no CHP (ραγ = 0) in Figure S1. When there is no CHP, all methods perform
well in Scenario 1 but point estimates from MR-LDP and RAPS are biased in Scenario 2.
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(a) Type-I error (b) Point estimate
(c) Type-I error (d) Point estimate
Figure 4: Comparisons of type-I error and point estimate using correlated SNPs with
ραγ = 0.2. The number of replicates for type-I error is 1,000 and that for point estimates is
100. The top and bottom panels are corresponding to Scenario 1 and Scenario 2, respective.
Note that we evaluate type-I error for CAUSE, GSMR, MRMix and RAPS using either all
SNPs or independent SNPs.
5 Real Data Analysis
5.1 Real validations
Clearly, when there is no horizontal pleiotropy either correlated or independent, in other
words, ηk = 0,∀k , the proposed MR-Corr reduces to the classical MR methods that Eqn. (4)
holds. Here, we used real datasets for height as both exposure and outcome to compare the
estimates from MR-Corr and MR-Corr2 with those from the other five alternative methods.
As the exposure and outcome are the same complex traits, the causal effect β0 can be taken
as known, i.e., β0 = 1. Since this type of analysis estimates the causal effects with known
effect sizes under no horizontal pleiotropy, we make comparisons among the proposed and
alternative methods to see the effectiveness of accounting for weak instrumental variants in
LD.
In this validation study, we treated the summary statistics for height in UK Biobank [7] as
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the screening dataset, and chose the summary statistics for height in male and females in an
European population-based study [33] as exposure and outcome, respectively. In the analysis,
we first selected SNPs under different p-value threshold as instrumental variants. We next
conducted SNP-clumping to obtain near-independent SNPs using PLINK [31] for MR-Corr,
CAUSE, GSMR, MRMix and RAPS. For both MR-Corr2 and MR-LDP, we conducted the
analysis using all SNPs and used the genotype data from UK10K project [11] merged with
1000 Genome Project Phase 3 [10] as the reference dataset. The estimated causal effects
with their corresponding standard errors using seven methods are summarized in Table 1.
Clearly, 95% confidence intervals from MR-Corr, MR-Corr2, MR-LDP, MRMix and RAPS
cover the true β0 but not for CAUSE and GSMR. Comparing to MR-Corr2, MR-LDP and
RAPS, the standard errors from MRMix are very large. On the other hand, using more
correlated instrumental variants improves estimation efficiency for MR-Corr2 and MR-LDP
as both methods used SNPs in LD. This validation study demonstrates that the proposed
methods perform well when there is no horizontal pleiotropy Eqn. (4). Moreover, methods
using correlated SNPs, i.e., MR-Corr2 and MR-LDP, are more statistically efficient.
Table 1: Results for height-height example. We chose 10 different p-value thresholds, psel, to select
instrumental variants from 5 × 10−8 to 1 × 10−3, and reported the estimated causal effects with their
corresponding standard errors for all six methods. Note that SNP clumping was performed to obtain
independent SNPs for MR-Corr, CAUSE, GSMR, MRMix and RAPS.
psel MR-Corr2 MR-LDP MR-corr CAUSE GSMR MRMix RAPS
5e-08 1.010(0.019) 1.022(0.020) 1.012(0.026) 1.428(0.085) 0.789(0.021) 0.805(1.807) 1.015(0.034)
1e-07 1.011(0.020) 1.024(0.020) 1.015(0.029) 1.426(0.085) 0.784(0.021) 0.800(6.841) 1.019(0.035)
5e-07 1.007(0.020) 1.023(0.019) 1.010(0.028) 1.422(0.086) 0.738(0.020) 0.825(1.710) 1.017(0.036)
1e-06 1.005(0.018) 1.020(0.019) 1.005(0.028) 1.413(0.087) 0.730(0.019) 0.780(0.396) 1.008(0.036)
5e-06 1.001(0.019) 1.020(0.019) 1.011(0.029) 1.391(0.089) 0.709(0.019) 0.765(0.276) 1.018(0.039)
1e-05 1.001(0.019) 1.018(0.018) 0.996(0.030) 1.346(0.090) 0.694(0.019) 0.800(0.639) 1.004(0.039)
5e-05 0.996(0.018) 1.017(0.018) 0.992(0.031) 1.320(0.093) 0.649(0.018) 0.790(1.573) 0.997(0.042)
1e-04 0.997(0.019) 1.018(0.018) 0.985(0.028) 1.317(0.093) 0.627(0.017) 0.560(0.573) 0.991(0.043)
5e-04 0.989(0.018) 1.017(0.017) 0.982(0.032) 1.235(0.099) 0.562(0.017) 0.570(0.479) 1.006(0.053)
5.2 MR analysis for GWAS summary statistics
In the real data analysis, we applied six methods that are used in validation studies to
analyze the causal effects between exposure-outcome pairs among two sets of traits. The first
set contains ten traits, including low density lipoprotein cholesterol (LDL-c), high density
lipoprotein cholesterol (HDL-c), total cholesterol (TC), triglycerides (TG), glucose, body fat
percentage (BFP), total bone mineral density (BMD), body mass index (BMI), coronary
artery disease (CAD), type 2 diabetes (T2D). The second set has five psychiatric disorders,
including attention deficit hyperactivity disorder (ADHD), major depression disorder (MDD),
bipolar disorder (BIP), schizophrenia (SCZ) and autism spectrum disorder (ASD). In the
analysis using CAUSE, MRMix, GSMR and RAPS, we used r2 = 0.1 to perform SNP
clumping by CAUSE default. The results are shown in Figure 5 for MR-Corr2, CAUSE,
MRMix, GSMR, MR-LDP, and RAPS, respectively.
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In the first set, since we conducted MR analysis for 10× 9 = 90 exposure-outcome pairs,
we performed Bonferroni correction for significance level. In Figure 5, we identified 39, 11, 27,
45, 37 and 40 significant causal pairs using MR-Corr2, CAUSE, MRMix, GSMR, MR-LDP,
and RAPS, respectively. In details, many MR methods not correcting for CHP identified the
significant causal effect of LDL-c on T2D [29]. But after correcting for CHP, MR-Corr2 did
not identify it significantly. One of the driving cause of T2D is insulin resistance [21]. And it
is known that insulin resistance had profound effects on lipoproteins including LDL-c [16].
So the variants associated with insulin resistance could affect both T2D and LDL-c level,
which is a case of CHP. As both BMI and BFP measure the level obesity, all six methods
identified significant reverse causality between BMI and BFP with effect size close to 1,
implying that the causal outcomes for BMI should be similar to those for BFP. As shown
in Figure 5(a), both BMI and BFP are causally related to T2D based on our MR-Corr2
test. However, all the other methods identified only one of them as the causal risk factor
for T2D. It is known that both normal weight individuals with high BFP and overweight
individuals with low BFP have higher risk for prediabetes or diabetes [20]. Therefore, only
our method can uncover this combined effect of BMI and BFP on T2D. Other than T2D, we
also consistently observe this combined effect on CAD as well as several metabolite levels.
Besides BMI and BFP, we also identified two reverse causalities of T2D. One of them is T2D
and glucose, which is expected because the most important characteristics of T2D is high
fasting blood glucose [13]. The other novel reverse causality exits between T2D and BMD,
which is consistent with the previous findings that BMD is increased in T2D patients [38].
Though the causal roles of LDL-c and TG on CAD are confirmed in different clinical
trials [26], but it is not clear for the role of TC on CAD. After Bonferroni correction, MR-
Corr2 did not estimate the casual effect significantly between HDL-c and CAD but identified
significantly by GSMR, MR-LDP and RAPS. Our result of MR-Corr2 is consistent with
those from clinical trials that use CETP inhibitor to raise the HDL-c level, but does not
result in a lower rate of cardiovascular disease [25]. Recent studies show that patients with
diabetes are at a substantially increased risk of dying from cardiovascular disease [15] while
a recent trial shows that the beneficial effects of a sodium-glucose co-transporter 2 (SGLT2)
inhibitor on prevention of hospitalization for heart failure therefore represent a significant
clinical breakthrough [28]. The analysis using MR-Corr2, MRMix, GSMR and MR-LDP
confirms these established causal relationships.
In addition, we also observe several reverse causalities among lipid metabolites, which
are TC-HDL-c, TC-LDL-c, and TG-LDL-c. These relationships are expected because they
are naturally related with each other. For example, TC is a measure of LDL-c, HDL-c, and
other lipid components, and LDL-c level can be calculated from TG [8].
For the second set of traits, we studied the causal relationships among psychiatric
disorders. Since we conducted MR analysis for 5 × 4 = 20 exposure-outcome pairs, we
performed Bonferroni correction for significance level. It is well-known genetic correlations
among psychiatric disorders are high, primarily due to the fact that common risk variants
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for psychiatric disorders are correlated significantly [1]. In Figure S4 (Supplementary), we
identified 8, 0, 2, 7, 7 and 6 significant causal pairs using MR-Corr2, CAUSE, MRMix,
GSMR, MR-LDP, and RAPS, respectively. MR-Corr2 identified four psychiatric disorders to
be causally affected by MDD while RAPS and MR-LDP identify three, GSMR identifies two,
and MRMix identified one among the four identified by MR-Corr2. Meanwhile, MR-Corr2,
MR-LDP, GSMR and RAPS identified a significant positive causal effect of SCZ on ASD, BIP
and MDD, and MR-Corr2 , MR-LDP and GSMR identified a significant positive causal effect
of ASD on ADHD. Table S2 in the Supplementary document shows the genetic correlations
among these psychiatric disorders in [1]. A general pattern is that a significant correlation
usually implies a causal relationship except for pairs in ADHD-BIP and ADHD-SCZ. These
causal relationships may be attributable to the existence of a large number of medical
comorbidities in psychiatric disorders [30]. The detailed results for causal inference and Venn
plot for psychiatric disorders are shown in Table S3 and Figure S5 in the Supplementary
document.
6 Discussion
In this study, we proposed MR-Corr2 to account for CHP in the presence of correlated genetic
variants. Mitigating the impact of CHP is important in MR/IV methods. We proposed a
MLR strategy that first decomposes the direct effects into two parts, linear and orthogonal,
then reparameterizes the relationship between γ and Γ. In this way, the impact of CHP can
be mitigated using model with variable selection, e.g., a spike-slab prior is used here. To
incorporate correlated SNPs, we use an approximated distribution for summary statistics.
Our validation studies which include both a real validation and simulations demonstrate that
MR-Corr2 controls type-I error at its nominal level and estimates the causal effects unbiasedly.
In real data analysis, MR-Corr2 did not identify the contradictory causal relationship between
HDL-c and CAD, but identified multiple health outcomes, i.e., T2D, CAD, TG, and HDL-c,
affected by obese risk factors (BMI and BFP) causally.
The proposed MLR strategy provides an effective and systematic framework to mitigate
the impact of CHP in MR/IV methods. By connecting MLR strategy with CAUSE, it offers
a unique perspective from correlated pleiotropy that is genetic variants affect unobserved
confounders as shown in Figure 3b. When there exist both correlated pleiotropy and IHP, an
ideal model should allow linear relationship (4) deviates with IHP. Specifically, other than
using Eqn. (7), we now can model an additional IHP, θk, as
Γk =
{
β0γk + θk, α˜k = 0
β1γk + θk + α˜k, α˜k 6= 0.
(16)
In this way, we will be able to handle both correlated pleiotropy as well as independent
horizontal pleiotropy in the sense of CAUSE.
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The other limitation of the proposed methods is that they do not account for sample
overlap between SNP-exposure and SNP-outcome. For example, the samples are largely
overlapped for lipid traits, i.e., HDL-c, LDL-c, TC and TC. Without correcting for these
overlapped samples, the hypothesis test for causal effects between lipid traits tend to be
inflated. We plan to address these challenges in future work.
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(a) MR-Corr2 (b) CAUSE
(c) MRMix (d) GSMR
(e) MR-LDP (f) RAPS
Figure 5: Estimated causal effects and their significance between exposure-outcome pairs
among nine traits. In this plot, we show the magnitude (|βˆ0) and direction (+ or -) of
estimated causal effects together with their significance level (− log10(p-value)).
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